| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | PLXNC1; VESPR; PLXN-C1 |
| Entrez GeneID | 10154 |
| clone | 2H11C11 |
| WB Predicted band size | 175.7kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human CD232 (AA: extra 35-234) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于CD232抗体的3篇参考文献示例(注：CD232可能指不同靶点，如VEGFR-3或Plexin C1.以下为模拟文献内容)：
---
1. **文献名称**：*Targeting VEGFR-3/CD232 in Tumor Lymphangiogenesis and Metastasis*
**作者**：Smith A, et al.
**摘要**：该研究开发了一种抗CD232(VEGFR-3)单克隆抗体，通过阻断VEGF-C信号通路抑制肿瘤相关淋巴管生成，显著降低小鼠模型中乳腺癌的淋巴结转移。
2. **文献名称**：*Anti-CD232/Plexin C1 Antibody Modulates Tumor Microenvironment in Glioblastoma*
**作者**：Brown K, et al.
**摘要**：研究发现CD232(Plexin C1)在胶质母细胞瘤中高表达，使用特异性抗体靶向后可抑制肿瘤细胞侵袭性，并重塑免疫微环境，提示其作为治疗靶点的潜力。
3. **文献名称**：*Humanized Anti-CD232 Antibody Enhances T-cell Response in Solid Tumors*
**作者**：Lee J, et al.
**摘要**：报道了一种人源化抗CD232抗体的设计与功能验证，显示其通过阻断免疫抑制信号通路，增强T细胞活性，为联合免疫治疗提供新策略。
---
**注**：以上文献为示例，实际研究中需通过学术数据库(如PubMed、Web of Science)检索具体文献。若CD232指向其他靶点，建议结合其基因名(如LYVE-1、Plexin C1)进一步筛选。
CD232. also known as VSTM1 (V-set and transmembrane domain-containing protein 1), is a cell surface glycoprotein belonging to the immunoglobulin superfamily. Identified as part of immune receptor signaling pathways, it is expressed on subsets of immune cells, including T cells and natural killer (NK) cells. CD232 has garnered interest for its potential role in modulating immune responses, though its exact biological function remains under investigation. Early studies suggest it may act as a co-stimulatory or co-inhibitory checkpoint molecule, influencing T-cell activation and cytokine production.
Antibodies targeting CD232 are primarily used as research tools to explore its expression patterns, ligand interactions, and mechanistic contributions to immune regulation. Some preclinical studies indicate that anti-CD232 antibodies could enhance or suppress immune activity depending on context, making it a candidate for immunotherapy development, particularly in cancer or autoimmune diseases. However, clinical relevance remains speculative, with limited data on its therapeutic targeting.
Current research focuses on characterizing CD232's structure, binding partners (e.g., putative ligands like VSIR), and signaling cascades. Its dual Ig-like domains and transmembrane region suggest involvement in cell-cell communication. While still in exploratory stages, CD232 antibodies hold promise for advancing understanding of immune modulation and may inspire novel therapeutic strategies as mechanistic insights evolve.
×
